Medincell SA Reports Full Year 2026 Earnings, Highlights Strategic Growth and Challenges

Earnings
โดย GuruFocus·Read original
Summary · why it matters

Medincell SA reported full year 2026 earnings, highlighting progress in its Shift to Growth strategy and a rise in royalties from UZD, while total income dipped to $24.3 million from $27.7 million a year earlier due to the absence of milestone payments. Net sales of UZD by Teva reached $215 million, up from $141 million, and Olanzapine LAI is on track for a U.S. launch in the fourth quarter of 2026 with FDA submissions accepted. Operating expenses increased to EUR 45 million from EUR 38.5 million, resulting in an operating loss of EUR 20.8 million, though the company maintains a strong cash position of EUR 85 million. CEO Christophe Duarte noted Teva's conservative guidance and expects Olanzapine LAI to launch immediately upon approval, while CFO Stefan Postic addressed foreign exchange exposure by aligning expenses with USD revenues where possible. The company is expanding its pipeline with 15 active programs and confirmed that AbbVie's first candidate will start clinical development in 2027.

Impact on stocks 3

Health Care▲ · 2 stocks
Medincell SA
MEDCL
▲ PositiveCapitalrelevance

Reported full year 2026 earnings, highlighting strategic growth and strong cash position of EUR 85 million.

Biotech & Genomic Medicine▲ · 1 stocks
AbbVie Inc
ABBV
± MixedTechnologyrelevance

AbbVie's first candidate will start clinical development in 2027, but no further details on impact.

© 2026 MarketDXNews